NTRK2
Showing 1 - 25 of 84
NTRK Family Gene Mutation Trial in Germany
Recruiting
- NTRK Family Gene Mutation
-
Berlin, Germany
- +22 more
Jan 18, 2023
Optimize Detection of NTRK1,2,3 Fusions in Thyroid Cancer
Recruiting
- Thyroid Cancer
- NTRK fusion assessment
-
Roma, ItalyRegina Elena National Cancer Institute
Mar 31, 2023
Solid Tumor Trial (TL118 Capsule)
Not yet recruiting
- Solid Tumor
- TL118 Capsule
- (no location specified)
Aug 18, 2023
Advanced Solid Tumors Harboring NTRK Fusion, Primary CNS Tumors Harboring NTRK Fusion Trial in Guangzhou (ICP-723)
Recruiting
- Advanced Solid Tumors Harboring NTRK Fusion
- Primary Central Nervous System Tumors Harboring NTRK Fusion
-
Guangzhou, Guangdong, ChinaSun Yat-Sen University Cancer Center
Feb 16, 2023
Locally Advanced Solid Tumors, Metastatic Solid Tumors Trial in Korea, Republic of, United States (Entrectinib)
Completed
- Locally Advanced Solid Tumors
- Metastatic Solid Tumors
-
Orange, California
- +9 more
Jun 7, 2021
Soft Tissue Sarcoma, Advanced Cancer, Metastatic Cancer Trial in France (Blood and tumor samples)
Recruiting
- Soft Tissue Sarcoma
- +2 more
- Blood and tumor samples
-
Clermont-Ferrand, France
- +9 more
Dec 8, 2021
Solid Tumors Harboring NTRK Fusion Trial in Worldwide (Selitrectinib (BAY2731954))
Active, not recruiting
- Solid Tumors Harboring NTRK Fusion
- Selitrectinib (BAY2731954)
-
La Jolla, California
- +28 more
Aug 18, 2022
Solid Tumors Harboring NTRK Fusion Trial in Worldwide (Larotrectinib (Vitrakvi, BAY2757556))
Recruiting
- Solid Tumors Harboring NTRK Fusion
- Larotrectinib (Vitrakvi, BAY2757556)
-
Los Angeles, California
- +50 more
Jan 29, 2023
Locally Advanced Solid Tumors, Metastatic Solid Tumors Trial in Worldwide (Oral repotrectinib (TPX-0005))
Recruiting
- Locally Advanced Solid Tumors
- Metastatic Solid Tumors
- Oral repotrectinib (TPX-0005)
-
Yuma, Arizona
- +175 more
Jan 25, 2023
Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma Trial in Worldwide (Oral repotrectinib (TPX-0005))
Recruiting
- Locally Advanced Solid Tumors
- +3 more
- Oral repotrectinib (TPX-0005)
-
Los Angeles, California
- +27 more
Aug 9, 2022
Cancer, Cancer Metastatic, NTRK Gene Fusion Overexpression Trial in Worldwide (Data collection and quality of life
Recruiting
- Cancer
- +15 more
- Data collection and quality of life questionnaire
-
Graz, Austria
- +40 more
Jul 27, 2021
Solid Tumors Harboring NTRK Fusion Trial in Worldwide (BAY2757556 (Larotrectinib, Vitrakvi))
Recruiting
- Solid Tumors Harboring NTRK Fusion
- BAY2757556 (Larotrectinib, Vitrakvi)
-
Palo Alto, California
- +158 more
Aug 8, 2022
Solid Tumors Harboring NTRK Fusion Trial in Glendale, Baltimore (Selitrectinib (BAY2731954) Adult tablet, Selitrectinib
Completed
- Solid Tumors Harboring NTRK Fusion
- Selitrectinib (BAY2731954) Adult tablet
- +3 more
-
Glendale, California
- +1 more
Aug 24, 2021
ALK Fusion Protein Expression, BRAF wt Allele, Invasive Skin Melanoma Trial in San Francisco (Capmatinib, Ceritinib,
Terminated
- ALK Fusion Protein Expression
- +14 more
- Capmatinib
- +4 more
-
San Francisco, CaliforniaUniversity of California, San Francisco
Jan 14, 2020
Solid Tumors Harboring NTRK Fusion Trial (Selitrectinib (BAY2731954))
No longer available
- Solid Tumors Harboring NTRK Fusion
- Selitrectinib (BAY2731954)
- (no location specified)
Sep 8, 2021
Biliary Tract Tumors, Gastric Cancer, Esophageal Squamous Cell Carcinoma Trial in Beijing (FGFR Inhibitor, IDH1 Inhibitor, HER2
Unknown status
- Biliary Tract Neoplasms
- +8 more
- FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al.
- Other Therapy
-
Beijing, Beijing, ChinaPeking University Cancer Hospital
Oct 8, 2020
Obesity, Child Trial (sequencing of a panel of 14 genes in leptin melanocortin pathway)
Not yet recruiting
- Obesity, Child
- sequencing of a panel of 14 genes in leptin melanocortin pathway
- (no location specified)
Jul 3, 2023
Advanced Malignant Solid Tumor, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma Trial in
Recruiting
- Advanced Malignant Solid Neoplasm
- +44 more
- Biopsy
- +23 more
-
Birmingham, Alabama
- +166 more
Feb 2, 2023
A Retro-/Prospective, Non-interventional, Cohort Study in Adult
Active, not recruiting
- Solid Tumor, Adult
- +2 more
-
Amiens, France
- +3 more
Jul 22, 2022
Solid Tumors Harboring NTRK Fusion Trial in United States (Larotrectinib (Vitrakvi, BAY2757556))
Completed
- Solid Tumors Harboring NTRK Fusion
- Larotrectinib (Vitrakvi, BAY2757556)
-
Aurora, Colorado
- +7 more
May 11, 2021
NSCLC, Solid Tumor Trial in Boston (Merestinib)
Active, not recruiting
- Carcinoma, Non-Small-Cell Lung
- Solid Tumor
-
Boston, Massachusetts
- +1 more
Jan 26, 2022
Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma, Neoadjuvant or Conversion Therapy, Precision Therapy Trial in
Recruiting
- Locally Advanced or Recurrent/Metastatic Salivary Gland Carcinoma
- +2 more
- Vedolizumab
- +5 more
-
Beijing, Beijing, China
- +1 more
Nov 21, 2023